Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications

Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction

(2015) Edward P. Carter et al.   TRENDS IN CELL BIOLOGY

Abstract 5449: FP-1039/GSK3052230, an FGF ligand trap, enhances VEGF antagonist therapy in preclinical models of RCC and HCC

(2015) David I. Bellovin et al.   CANCER RESEARCH

Abstract CT325: First in human study of JNJ-42756493, a potent pan fibroblast growth factor receptor (FGFR) inhibitor in patients with advanced solid tumors

(2015) Rodrigo Dienstmann et al.   CANCER RESEARCH

Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms

(2015) Jennifer J. Wheler et al.   Oncotarget

The N550K/H Mutations in FGFR2 Confer Differential Resistance to PD173074, Dovitinib, and Ponatinib ATP-Competitive Inhibitors

(2015) Sara A Byron et al.   NEOPLASIA

Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072

(2014) B. Kasper et al.   ANNALS OF ONCOLOGY

Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors

(2014) J.- C. Soria et al.   ANNALS OF ONCOLOGY

Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance

(2014) N. Javidi-Sharifi et al.   CANCER RESEARCH

HER2 aberrations in cancer: Implications for therapy

(2014) Min Yan et al.   CANCER TREATMENT REVIEWS

Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial

(2014) Robert J Motzer et al.   LANCET ONCOLOGY

Abstract A270: TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities.

(2014) H. Ochiiwa et al.   MOLECULAR CANCER THERAPEUTICS

The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor

(2014) Y. Nakanishi et al.   MOLECULAR CANCER THERAPEUTICS

Comprehensive molecular characterization of gastric adenocarcinoma

(2014) Adam J. Bass et al.   NATURE

Comprehensive molecular profiling of lung adenocarcinoma

(2014) Eric A. Collisson et al.   NATURE

Comprehensive molecular characterization of urothelial bladder carcinoma

(2014)   NATURE

INTEGRATIVE GENOMIC CHARACTERIZATION OF LOWER GRADE GLIOMAS

(2014) D. J. Brat et al.   NEURO-ONCOLOGY

Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib

(2014) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

(2014) Luca Richeldi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib versus Methotrexate in Rheumatoid Arthritis

(2014) Eun Bong Lee et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular Tumor Board: The University of California San Diego Moores Cancer Center Experience

(2014) M. Schwaederle et al.   ONCOLOGIST

Novel Insight into Mutational Landscape of Head and Neck Squamous Cell Carcinoma

(2014) Daria A. Gaykalova et al.   PLoS One

Patient-derived models of acquired resistance can identify effective drug combinations for cancer

(2014) Adam S. Crystal et al.   SCIENCE

Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer

(2014) R C Turkington et al.   Cell Death & Disease

Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors

(2014) Ravi Salgia   Cancer Medicine

Germline mutations inFGFreceptors and medulloblastomas

(2013) Franck Bourdeaut et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART A

Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors

(2013) R. Dienstmann et al.   ANNALS OF ONCOLOGY

Inhibitor-Sensitive FGFR2 and FGFR3 Mutations in Lung Squamous Cell Carcinoma

(2013) R. G. Liao et al.   CANCER RESEARCH

Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma

(2013) Yasuhito Arai et al.   HEPATOLOGY

FGFR1 and FGFR2 Mutations in Pfeiffer Syndrome

(2013) Chayanin Chokdeemboon et al.   JOURNAL OF CRANIOFACIAL SURGERY

Activity of the Fibroblast Growth Factor Receptor Inhibitors Dovitinib (TKI258) and NVP-BGJ398 in Human Endometrial Cancer Cells

(2013) G. E. Konecny et al.   MOLECULAR CANCER THERAPEUTICS

Fibroblast Growth Factor Receptor 3 Is a Rational Therapeutic Target in Bladder Cancer

(2013) K. M. Gust et al.   MOLECULAR CANCER THERAPEUTICS

Comprehensive molecular characterization of clear cell renal cell carcinoma

(2013)   NATURE

Integrated genomic characterization of endometrial carcinoma

(2013) Gad Getz et al.   NATURE

The mutational landscape of adenoid cystic carcinoma

(2013) Allen S Ho et al.   NATURE GENETICS

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

(2013) J.E. Cortes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Postnatal Soluble FGFR3 Therapy Rescues Achondroplasia Symptoms and Restores Bone Growth in Mice

(2013) S. Garcia et al.   Science Translational Medicine

Identification of Targetable FGFR Gene Fusions in Diverse Cancers

(2013) Yi-Mi Wu et al.   Cancer Discovery

Molecular basis for the Kallmann syndrome-linked fibroblast growth factor receptor mutation

(2012) Ryan D. Thurman et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Mechanisms of FGFR-mediated carcinogenesis

(2012) Imran Ahmad et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure

(2012) Hielke J. Meulenbeld et al.   BJU INTERNATIONAL

FGFR2 gene amplification and clinicopathological features in gastric cancer

(2012) K Matsumoto et al.   BRITISH JOURNAL OF CANCER

A Landscape of Driver Mutations in Melanoma

(2012) Eran Hodis et al.   CELL

Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing

(2012) Marcin Imielinski et al.   CELL

Cross-talk between FGF and other cytokine signalling pathways during endochondral bone development

(2012) Min Jin et al.   CELL BIOLOGY INTERNATIONAL

Translating the Therapeutic Potential of AZD4547 in FGFR1-Amplified Non-Small Cell Lung Cancer through the Use of Patient-Derived Tumor Xenograft Models

(2012) J. Zhang et al.   CLINICAL CANCER RESEARCH

Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative

(2012) A.-M. Tsimberidou et al.   CLINICAL CANCER RESEARCH

Endocrine fibroblast growth factors 15/19 and 21: from feast to famine

(2012) M. J. Potthoff et al.   GENES & DEVELOPMENT

Oncogenic FGFR3 gene fusions in bladder cancer

(2012) Sarah V. Williams et al.   HUMAN MOLECULAR GENETICS

FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma

(2012) Eleonora Brunello et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

FGFR1 Amplification in Squamous Cell Carcinoma of The Lung

(2012) Rebecca S. Heist et al.   Journal of Thoracic Oncology

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) George D Demetri et al.   LANCET

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) Axel Grothey et al.   LANCET

The Tyrosine Kinase Inhibitor E-3810 Combined with Paclitaxel Inhibits the Growth of Advanced-Stage Triple-Negative Breast Cancer Xenografts

(2012) E. Bello et al.   MOLECULAR CANCER THERAPEUTICS

Sequence analysis of mutations and translocations across breast cancer subtypes

(2012) Shantanu Banerji et al.   NATURE

Recurrent R-spondin fusions in colon cancer

(2012) Somasekar Seshagiri et al.   NATURE

Comprehensive molecular characterization of human colon and rectal cancer

(2012)   NATURE

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Comprehensive genomic characterization of squamous cell lung cancers

(2012)   NATURE

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance

(2012) V Chell et al.   ONCOGENE

FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features

(2012) Sara A. Byron et al.   PLoS One

Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma

(2012) D. Singh et al.   SCIENCE

FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor

(2012) V. Guagnano et al.   Cancer Discovery

Rescue Screens with Secreted Proteins Reveal Compensatory Potential of Receptor Tyrosine Kinases in Driving Cancer Growth

(2012) Fred Harbinski et al.   Cancer Discovery

E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models

(2011) Ezia Bello et al.   CANCER RESEARCH

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase

(2011) Vito Guagnano et al.   JOURNAL OF MEDICINAL CHEMISTRY

FOXO1–FGFR1 fusion and amplification in a solid variant of alveolar rhabdomyosarcoma

(2011) Jinglan Liu et al.   MODERN PATHOLOGY

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

From Cradle to Grave: The Multiple Roles of Fibroblast Growth Factors in Neural Development

(2011) François Guillemot et al.   NEURON

Muenke syndrome with pigmentary disorder and probable hemimegalencephaly: An expansion of the phenotype

(2010) Ghada M. H. Abdel-Salam et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART A

Integrative Genomic Profiling of Human Prostate Cancer

(2010) Barry S. Taylor et al.   CANCER CELL

MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor

(2010) B.-S. Pan et al.   CANCER RESEARCH

FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer

(2010) N. Turner et al.   CANCER RESEARCH

Biology of FGFRL1, the fifth fibroblast growth factor receptor

(2010) Beat Trueb   CELLULAR AND MOLECULAR LIFE SCIENCES

Increased EFG- and PDGF -receptor signaling by mutant FGF-receptor 2 contributes to osteoblast dysfunction in Apert craniosynostosis

(2010) H. Miraoui et al.   HUMAN MOLECULAR GENETICS

8p11 myeloproliferative syndrome: a review

(2010) Courtney C. Jackson et al.   HUMAN PATHOLOGY

Physical Basis behind Achondroplasia, the Most Common Form of Human Dwarfism

(2010) Lijuan He et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Nonsense Mutations inFGF8Gene Causing Different Degrees of Human Gonadotropin-Releasing Deficiency

(2010) Ericka B. Trarbach et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy

(2010) Jordi Barretina et al.   NATURE GENETICS

Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer

(2010) J. Weiss et al.   Science Translational Medicine

Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate

(2009) Christine Y. Shiang et al.   BREAST CANCER RESEARCH AND TREATMENT

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

(2009) Thomas O'Hare et al.   CANCER CELL

A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors

(2009) R. B. Cohen et al.   CLINICAL CANCER RESEARCH

The FGFRL1 Receptor Is Shed from Cell Membranes, Binds Fibroblast Growth Factors (FGFs), and Antagonizes FGF Signaling inXenopusEmbryos

(2009) Florian Steinberg et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Loss-of-Function Fibroblast Growth Factor Receptor-2 Mutations in Melanoma

(2009) Michael G. Gartside et al.   MOLECULAR CANCER RESEARCH

The FGF family: biology, pathophysiology and therapy

(2009) Andrew Beenken et al.   NATURE REVIEWS DRUG DISCOVERY

Muenke syndrome with osteochondroma

(2008) Mafalda Barbosa et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART A

Sprouty proteins, masterminds of receptor tyrosine kinase signaling

(2008) Miguel A. Cabrita et al.   ANGIOGENESIS

Characterization of the first FGFRL1 mutation identified in a craniosynostosis patient

(2008) Thorsten Rieckmann et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Prediction of Cancer Driver Mutations in Protein Kinases

(2008) A. Torkamani et al.   CANCER RESEARCH

Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma

(2008) H. Huynh et al.   CLINICAL CANCER RESEARCH

Actions and Mode of Actions of FGF19 Subfamily Members

(2008) Seiji FUKUMOTO   ENDOCRINE JOURNAL

Novel therapeutic targets in bladder cancer: mutation and expression of FGF receptors

(2008) Margaret A Knowles   Future Oncology

Somatic mutations affect key pathways in lung adenocarcinoma

(2008) Li Ding et al.   NATURE

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE

Ovarian dysgerminoma and Apert syndrome

(2007) Cécile Rouzier et al.   PEDIATRIC BLOOD & CANCER